It is very uncertain whether vitamin E changes progression to late AMD (neovascular AMD, geographic atrophy or both) compared with placebo (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Vitamin E showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (low certainty).
The review found no eligible studies for this question.
Antioxidant multivitamin and mineral supplement probably leads to lower progression to neovascular AMD compared with placebo or no treatment (moderate certainty).
It is very uncertain whether vitamin E changes adverse effects compared with placebo (very low certainty).
The review found no eligible studies for this question.
Zinc probably leads to lower progression to late AMD (neovascular AMD, geographic atrophy or both) compared with placebo (moderate certainty).
Zinc probably leads to lower progression to neovascular AMD compared with placebo (moderate certainty).
Zinc showed no clear difference in progression to geographic atrophy compared with placebo (moderate certainty).
Zinc showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Antioxidant multivitamin and mineral supplement showed no clear difference in progression to geographic atrophy compared with placebo or no treatment (moderate certainty).
Antioxidant multivitamin and mineral supplement probably leads to lower progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo or no treatment (moderate certainty).
Antioxidant multivitamin and mineral supplement may leads to lower adverse effects compared with placebo or no treatment (low certainty).
The review found no eligible studies for this question.